Amylyx enters avexitide supply agreements with Bachem and Polypeptide; $30M upfront to Polypeptide

Amylyx Pharmaceuticals, Inc.

Paid or agreed $30M upfront fee to Polypeptide for capacity reservation under term sheet.
Bachem Manufacturing Agreement begins 2028 with minimum annual purchase quantities of avexitide drug substance.
Both suppliers are non-exclusive; Amylyx may use alternate manufacturers.
Supply prices adjusted annually for labor, utilities, overhead; terms auto-renew after 5 years.
Agreements cover commercial manufacturing of avexitide if regulatory approval is obtained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.